Overview

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study is to determine the safety, tolerability, and pharmacokinetics of two or three repeat intravenous (IV) bolus doses of regadenoson administered 10 minutes apart in healthy supine subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Treatments:
Regadenoson